Anaptysbio Stock Investor Sentiment

ANAB Stock  USD 16.73  0.11  0.65%   
About 67% of AnaptysBio's investor base is looking to short. The analysis of the overall investor sentiment regarding AnaptysBio suggests that many traders are alarmed. The current market sentiment, together with AnaptysBio's historical and current headlines, can help investors time the market. In addition, many technical investors use AnaptysBio stock news signals to limit their universe of possible portfolio assets.

Comfort Level 33

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use AnaptysBio's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward AnaptysBio.

AnaptysBio Historical Sentiment

Although AnaptysBio's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding AnaptysBio, such as negative comments on social media and news outlets, may cause fear in the market and push AnaptysBio's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of AnaptysBio.
  

AnaptysBio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards AnaptysBio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

AnaptysBio Maximum Pain Price Across June 20th 2025 Option Contracts

AnaptysBio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of AnaptysBio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of AnaptysBio's options.
a day ago at news.google.com         
Wells Fargo Predicts Up to 440 percent Rally for These 2 Strong Buy Stocks - Markets Insider
Google News at Macroaxis
3 days ago at benzinga.com         
Why Intel Shares Are Trading Higher By Over 10 Here Are 20 Stocks Moving Premarket
benzinga news
six days ago at news.google.com         
Rhumbline Advisers Grows Position in AnaptysBio, Inc. - Defense World
Google News at Macroaxis
over a week ago at news.google.com         
HC Wainwright Reaffirms Neutral Rating for AnaptysBio - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
AnaptysBio, Inc. Short Interest Up 54.4 percent in February
news
over a week ago at thelincolnianonline.com         
Leerink Partnrs Forecasts AnaptysBio FY2029 Earnings
news
over two weeks ago at thelincolnianonline.com         
AnaptysBio Shares Gap Up on Better-Than-Expected Earnings
news
over two weeks ago at simplywall.st         
AnaptysBio Full Year 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over two weeks ago at prnewswire.com         
ANABs Certificate Accreditation Program Issues Transition Plan for Latest Version of ANSIASTM E2659 ...
prnewswire News
over two weeks ago at finance.yahoo.com         
ANABs Certificate Accreditation Program Issues Transition Plan for Latest Version of ANSIASTM E2659 ...
Yahoo News
over two weeks ago at gurufocus.com         
Anaptys Announces Participation in March Investor Conferences
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Gurufocus Stories at Macroaxis
over two weeks ago at seekingalpha.com         
AnaptysBio GAAP EPS of -0.72 beats by 0.91, revenue of 43.11M
seekingalpha News
Far too much social signal, news, headlines, and media speculation about AnaptysBio that are available to investors today. That information is available publicly through AnaptysBio media outlets and privately through word of mouth or via AnaptysBio internal channels. However, regardless of the origin, that massive amount of AnaptysBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AnaptysBio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AnaptysBio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AnaptysBio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AnaptysBio alpha.

AnaptysBio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Ecor1 Capital, Llc of 65184 shares of AnaptysBio at 12.9182 subject to Rule 16b-3
12/30/2024
2
Acquisition by Ecor1 Capital, Llc of 13268 shares of AnaptysBio at 12.9268 subject to Rule 16b-3
12/31/2024
3
Acquisition by Ecor1 Capital, Llc of 6646 shares of AnaptysBio at 12.9506 subject to Rule 16b-3
01/02/2025
4
Disposition of 34678 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3
01/03/2025
5
Disposition of 17850 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3
01/06/2025
6
Acquisition by Eric Loumeau of 7288 shares of AnaptysBio subject to Rule 16b-3
01/16/2025
7
Acquisition by Schmid John P. of 16510 shares of AnaptysBio at 14.83 subject to Rule 16b-3
01/22/2025
8
Disposition of 6387 shares by Daniel Faga of AnaptysBio at 15.3 subject to Rule 16b-3
01/24/2025
9
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
02/03/2025
10
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
02/12/2025
11
AnaptysBio Surges 30.5 percent Is This an Indication of Further Gains
02/13/2025
12
AnaptysBio, Inc. Stock Rockets 29 percent As Investors Are Less Pessimistic Than Expected
02/14/2025
13
AnaptysBio GAAP EPS of -0.72 beats by 0.91, revenue of 43.11M
02/27/2025
14
AnaptysBio, Inc. Short Interest Up 54.4 percent in February
03/04/2025

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stocks Directory
Find actively traded stocks across global markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments